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InﬂammationActive infection with torquetenovirus (TTV) has been associated with an increased severity of diseases in
which inﬂammation plays a particularly important pathogenetic role. Here, we report that cloned DNA of a
genogroup 4 TTV (ViPiSAL) is an activator of proinﬂammatory cytokine production by murine spleen cells
and that the effect is mediated via toll-like receptor (TLR)9. The same DNA also increased the levels of
proinﬂammatory cytokines induced by two well-characterized TLR9 stimulants. Finally, in silico analyses of
the genomes of ViPiSAL and other TTVs revealed marked differences in the representation of CpG motifs
known to be most effective at activating immune cells via TLR9. These ﬁndings demonstrate for the ﬁrst time
that at least one TTV isolate has the potential to stimulate and co-stimulate inﬂammatory responses.
© 2009 Elsevier Inc. All rights reserved.Introduction
Torquetenovirus (TTV), the prototype of the anelloviruses, is
characterized by a roughly spherical non-enveloped 30- to 32-nm
capsid and a small, circular negative-sense single-stranded (ss) DNA
genome. Different TTV isolates are heterogeneous both in genome size
(∼3.5 to ∼3.9 kb) and in genome sequence (nucleotide [nt] diversity
up to over 50%), which has led to their classiﬁcation into 5 widely
diverse genogroups and numerous genotypes. However, the genetic
organization of TTV is well conserved. The coding region contains two
major open reading frames (ORFs)–ORF1 of ∼2.6 kb encoding the
nucleocapsid protein and a protein involved in DNA replication, ORF2
encoding a protein with putative phosphatase activity–and some
poorly conserved small ORFswith unknown functions. The non-coding
region (UTR) is relatively large, representing approximately 1/3 of the
genome, and encompasses a short domain highly conserved among all
anelloviruses, several regulatory elements believed to be important in
viral replication, and, as salient feature, a stretch of 80 to 160 nt with
unusually high G-C content (reviewed in Bendinelli and Maggi, 2005;
Hino and Miyata, 2007; de Villiers and zur Hausen, 2009).
The prevalence of TTV infection is well above 80% throughout the
world (Hino and Miyata, 2007; Ninomiya et al., 2008; Okamoto,
2009). Infection is acquired early in life or even in utero, and viremiaentre, Pisa University Hospital
of Pisa, Via San Zeno, 35-37,
ll rights reserved.persists for years or for life (Bendinelli et al., 2001; Maggi et al., 2003).
The virus is ubiquitous in the body, being readily detectable in nearly
all organs and tissues (Okamoto et al., 2001; Pollicino et al., 2003). TTV
loads in plasma and kinetics of replication are generally elevated,
being in the order of those of other chronic viremia-producing viruses
such as the human immunodeﬁciency and the hepatitis C viruses
(Maggi et al., 2001). Also, TTV is shed in abundance with many body
materials, including saliva, nasal ﬂuids, feces, genital secretions and
breast milk (Matsubara et al., 2000; Maggi et al., 2003; Bendinelli and
Maggi, 2005). Finally, most people harbor a mixture of TTV
genogroups and genotypes (Maggi et al., 2005).
Although, there is probably no other known human virus as
pervasive, pleomorphic, and polytropic as TTV, the attempts to ﬁnd a
direct causal link between TTV and human disease have so far been
unsuccessful (reviewed in de Villiers and zur Hausen, 2009). This,
however, does not exclude that TTV may harm the host in more subtle
ways, for example by aggravating the course of diseases due to
independent noxae. Indeed, studies have revealed interesting positive
correlations between infection with speciﬁc TTV genogroups or
especially active TTV replication and severity of certain diseases,
including AIDS, neoplasia, asthma and rheumatoid arthritis (Shibayama
et al., 2001; Pifferi et al., 2005; de Villiers et al., 2007; Maggi et al., 2004,
2007; Thom and Petrik, 2007). Since inﬂammation is a particularly
important component inmany if not all these diseases, we considered it
of interest to determine whether the DNA of TTV may represent a
stimulus for theproductionof proinﬂammatory cytokines. In fact, recent
studies have shown that, unlike that of mammals but similar to that of
bacteria, the DNA of some viruses directly or indirectly activates a
Fig. 1. Expression of selected cytokines gene in cultured spleen cells exposed to graded
doses of TTVDNAcomplexed or notwith lipofectin. ODN1826wasusedaspositive control.
Compound doses expressed per well. The p values for signiﬁcant differences are shown.
Fig. 2. Expression of IFNγ gene in cultured spleen cells exposed to salmon sperm DNA at
the dose of 24 μg and complexed or not with lipofectin. The effect of a similar dose of
TTV DNA is also shown. Compound doses expressed per well. The p values for
signiﬁcant differences are shown.
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macrophages and selected lymphocyte subpopulations, and drives the
production of proinﬂammatory cytokines, including interferon (IFN)γ,
interleukin (IL)6, and IL12 (Hochrein et al., 2004; Hayashi et al., 2006;
Sato et al., 2006; Takeuchi and Akira, 2009). The effect is mainly if not
solely due tounmethylated cytidyl guanosyl dinucleotides (CpG),which
are relatively frequent in bacterial and viral DNA but uncommon in
vertebrate genomes. In particular, to possess stimulatory activity
(stimulatory CpG or CpG-S) unmethylated CpG needs to be in speciﬁc
6-mer sequence contexts, while unmethylated CpG in other sequence
contexts is either inhibitory (CpG-I) or neutral, and CpG-S activity is
mediated by members of the toll-like receptor (TLR) family, more
precisely the endosomally localized TLR9 (Bauer et al., 2008; Kumagai et
al., 2008a, 2008b; Thompson and Iwasaki, 2008). Using a genogroup 4
TTV, the present study shows for the ﬁrst time that the DNA of TTV can
induce immune cells to produce and secrete IFNγ, IL6 and IL12 and that
the effect is mediated via TLR9.
Results
TTV DNA stimulates the expression of selected cytokine genes
Since the attempts to grow TTV in culture at levels that would
permit DNA extraction from virions have so far failed, we used TTVDNA representing the entire viral genome ampliﬁed in a bacterial
plasmid and denatured to render it ss. The DNA was ampliﬁed from
the plasma of a patient with rheumatoid arthritis that, as determined
with a panel of genogroup-speciﬁc PCR assays, had been found to be
positive for a TTV (ViPiSAL, accession number: EU889253; ref. Maggi
et al., 2007), the complete sequence of which segregated within
genogroup 4 (mean genetic distance from the other members of this
group, 34%) and diverged from the other TTV genogroups by over 70%.
In this experiment, mouse spleen cells were exposed ex vivo for 12 h
to graded doses of TTV DNA and then analyzed for content in IFNγ, IL6,
IL10, and IL12 mRNAs by reverse transcription real-time PCR assays
using GAPDH RNA for normalization. This timing was selected
because in preliminary experiments, it had provided the highest
levels of stimulation for all the cytokine genes investigated over the
24 h of incubation that were explored. Positive controls were spleen
cell cultures exposed to the well characterized TLR9 stimulant
ODN1826, while negative controls were cells exposed to lipofectin
alone or diluent alone. As shown by Fig. 1, TTV DNA added alone at 3
different doses had no detectable effects on expression levels of the
cytokine genes under test. However, when the same DNA was
complexed with the transfecting agent lipofectin (TTV-lipo) before
addition to the cultures, it produced a marked increase of IFNγ gene
expression, a moderate increase of IL6 gene expression, and a modest
increase of IL10 gene expression relative to the levels found in the
negative control cultures. These effects were TTV DNA dose-
dependent with peak responses observed at the dose of 24 μg per
well (Fig. 1) and, as shown by Fig. 2 for IFNγ gene expression, were
much greater than observed with a similar dose of salmon sperm
DNA, an unrelated DNA known to be little or non stimulatory
(Magnusson et al., 2001; Hasslung et al., 2003). In contrast, TTV DNA
regardless of whether complexed or not with lipofectin failed to
increase the expression of IL12 (Fig. 1). On the other hand, in a similar
experiment TTV DNA also failed to stimulate IL4 RNA production,
although control cultures exposed to Concanavalin A (ConA) showed
a 100-fold or more increase in the expression of this cytokine (Fig. 3).
TTV DNA stimulates the secretion of selected cytokines
In these experiments, we used a multiplex bead-based immuno-
assay to measure the levels of IFNγ, IL6, and IL4 protein in the
supernatant of spleen cells cultures exposed to 24 μg TTV-lipo. As
shown in Table 1, at all time points investigated TTV-lipo induced
levels of IFNγ and IL6 greatly enhanced relative to the ones produced
Fig. 3. Expression of IL4 gene in cultured spleen cells exposed to graded doses of TTV
DNA complexed or not with lipofectin. ConA was used as positive control. Compound
doses expressed per well.
Fig. 4. Effect of chloroquine treatment of spleen cells on the stimulation of selected
cytokine genes expression induced by TTV-lipo. ODN1826 and ConA were used as
positive TLR9-dependent and -independent stimuli, respectively. Compound doses
expressed per well. The p values for signiﬁcant differences are shown.
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the results obtained by examining cytokine RNAs, the increase in IFNγ
productionwas more pronounced than the increase in IL6 production.
Also consistent with the gene expression ﬁndings, TTV-lipo exerted
no appreciable effects on IL4 production.
TTV DNA stimulation of cytokine expression is mediated by TLR9
Since it appeared possible that the activation of cytokine
expression brought about by TTV DNA was mediated through one
or more TLRs, we examined whether it might be blocked by
pretreating the spleen cells with two distinct TLR inhibitors. The
ﬁrst compound used was chloroquine, which has long been regarded
as an inhibitor of TLRs in general but, more recently, has been shown
to be especially active on TLR9 (Lee et al., 2003). As depicted by Fig. 4,
at the concentration used chloroquine had no detectable effects on
spleen cell viability (trypan blue exclusion) but completely prevented
the activation of IFNγ, IL6, and IL10 RNA production by 24 μg TTV-lipo.
Furthermore, the inhibitory effect was conﬁrmed by measuring the
levels of IFNγ in the supernatant of the cultures (Table 2).
Interestingly, consistent with current views on chloroquine
speciﬁcity (Lee et al., 2003), the control wells that were included in
the above expression experiment showed that this compound
effectively blocked triggering of cytokine RNA expression byTable 1
Levels of selected cytokines in the supernatant of spleen cells exposed to TTV-lipo or
lipofectin alone and measured at selected times of culture.
Cytokine (time of culture) TTV-Lipo Lipofectin alone
IFNγ
8 h 16.7±3.0a,b 1.4±0.1
12 h 26.7±3.3b 2.1±1.8
16 h 35.5±2.5c 1.5±0.2
IL6
18 h 22.5±4.1c 5.5±1.0
24 h 27.9±0.1b 4.1±0.3
IL4
18 h 0.6±0.2 0.9±0.1
24 h 0.9±0.5 0.5±0.1
a Mean pg /ml±SD.
b Statistically different from lipofectin alone at pb0.01 (Student's t test).
c Statistically different from lipofectin alone at pb0.05 (Student's t test).ODN1826 but was much less active if at all when the stimulant was
ConA, known to act through TLR9-independent mechanisms (Fig. 4).
Thus, taken together the results of the experiment strongly argued in
favor of the possibility that TLR9 was a major if not the only mediator
of TTV-lipo stimulation. To investigate this possibility further, we used
the RNA interference strategy for speciﬁcally silencing TLR9. Spleen
cells cultures were transfected with TLR9-speciﬁc siRNAs as described
in Material and methods, then exposed to 24 μg TTV-lipo or to 5 μg
ConA and 12 h later tested for IFNγ expression.While, as expected, the
treatment reduced only marginally the activating effect of ConA, it
reduced TTV-lipo activity by approximately 80% (Fig. 5).
TTV DNA potencies the activity of other TLR9 stimulants
Given the above results, it was of interest to examine whether TTV
DNA might also act in concert with other TLR9 stimulants atTable 2
IFNγ levels in the 16 h supernatant of spleen mouse cells treated with TTV-lipo in the
presence or absence of chloroquine.
Preparation Chloroquine (10 mM) IFNγ (pg/ml±SD)
Diluent − 0.8±0.1
Diluent + 0.3±0.1
TTV-lipo (24 μg) − 34.0±2.9
TTV-lipo (24 μg) + 0.5±5.6 a
a Statistically different from the cultures with TTV-lipo alone at pb0.01 (Student's
t test).
Fig. 5. Effect of TLR9 silencing on IFNγ gene expression by spleen cells exposed to TTV-
lipo and, for comparison, ConA. Prior to the addition of the stimulants the spleen cells
were treated with the indicated dose of TLR9-speciﬁc siRNA as described under
Materials and methods. Compound doses expressed per well. The p value for signiﬁcant
differences is shown.
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these experiments were ODN1826 and Escherichia coli ssDNA. Fig. 6
depicts the results of a representative experiment in which different
doses of TTV DNA, complexed or not with lipofectin, were added to
spleen cell cultures treated with ODN1826. As shown, when ODN1826
was the only stimulant, IFNγ, IL6 and IL10 gene expression increased
approximately 20-fold, and the addition of TTV DNAwith no lipofectin
increased this response only at the highest dose used (24 μg) and only
very moderately. In contrast, a suboptimal dose of TTV-lipo (6 μg), but
not lipofectin alone, increased the responses of spleen cells to
ODN1826 and, in the case of IFNγ and IL6, the effect was veryFig. 6. Cytokines gene expression in spleen cells stimulated with ODN1826 in the
presence or absence of TTV DNA complexed or not with lipofectin. Compound doses
expressed per well. The p values for signiﬁcant differences are shown.pronounced. The results with E. coli ssDNA, albeit less striking, went in
the same direction. In this experiment, E. coli ssDNA was either
present or absent, and TTV DNAwas used at 1, 10 or 30 μg/well, while
lipofectin was present in all the cultures. As shown by Fig. 7, E. coli
ssDNA and TTV DNA produced the expected stimulations of cytokine
gene expression, and the combination of the two produced signiﬁ-
cantly augmented responses.
In silico analysis of the DNA of different TTVs as potential cytokines
stimulants
Since different TTVs varywidely in nt composition and sequence, it
is possible that they also differ in the ability to stimulate cytokine
responses. This possibility was examined by scanning the genomes of
different TTVs for published consensus CpG-S and CpG-I and, on the
basis of their frequencies, calculating the so-called CpG index, which
has been recently introduced to evaluate DNA molecules as putative
cytokine stimulants regardless of their size, nt composition, and
overall C+G content (Lundberg et al., 2003). ViPiSAL, used in the
above experiments, and 44 further isolates for which the full-length or
near full-length sequence was present in GenBank and representative
of all the 5 TTV genogroups currently recognized (minimum, 7 isolates
per group) were evaluated. As shown in Table 3, all exhibited
substantially lower contents of total CpG motifs than expected based
on random base usage. However, while the ratios between the
observed and the expected frequencies of CpG-I were rather uniform
throughout the isolates, in the case of CpG-S the same ratios were
widely different, ranging between approximately 20 and 125. As a
result, calculated CpG indexes varied extensively, ranging from
greater than 18 (putatively stimulatory) to −24 (putativelyFig. 7. Cytokines gene expression in spleen cells stimulated with E. coli ssDNA in the
presence of graded doses of TTV DNA, complexed or not with lipofectin. Compound
doses expressed per well. The p values for signiﬁcant differences are shown.
Table 3
Sequence analysis and calculated CpG index in 45 TTV genomes.
TTV No.
isolates
Genome Ratio between observed and expected
frequencies of indicated motifsa
CpG index e of
Size (kb) CpG per kb b Total CpG c CpG-Sd CpG-I d GenBank sequences f aligned segments g
Genogroup 1 12 3.838 h (3.755–3.853) 49.4 (38.7–59.1) 74.5 (64.2–82.9) 79.5 (69.1–113.9) 73.8 (62.7–79.6) 3.1 (-0.7–18.7) 4.0 (-2.8–15.3)
Genogroup 2 7 3.736 (3.705–3.792) 46.7 (42.6–52.4) 73.6 (71.4–84.2) 59.3 (20.1–125.6) 72.5 (70.5–85.9) -7.2 (-24.0–17.5) -3.9 (-19.0–17.0)
Genogroup 3 8 3.795 (3.759–3.818) 50.6 (42.6–54.7) 75.0 (70.4–80.0) 80.1 (39.4–87.4) 77.3 (67.5–82.1) 0.5 (-9.0–4.4) 2.5 (-5.9–6.9)
Genogroup 4 10 3.672 (3.570–3.729) 51.9 (48.7–61.6) 75.5 (72.9–80.3) 90.4 (66.3–120.9) 76.7 (72.2–81.3) 5.4 (-2.2–18.3) 4.9 (1.4–17.4)
Genogroup 5 8 3.752 (3.694–3.770) 46.9 (39.9–50.1) 71.5 (66.1–77.0) 67.4 (64.5–100.2) 79.5 (72.0–80.6) -3.7 (-10.5–6.8) -1.9(-12.4–4.7)
a Ratio between the frequency of CpG motifs observed and the one expected on the basis of genomic G+C content, if the bases were used randomly.
b No. of CpG hexamer motifs (NNCGNN) normalized to 1 kb and the one expected on the basis of genomic G +C content, if the bases were used randomly.
c Ratio between the frequency of total CpG hexamer motifs (NNCGNN).
d Consensus CpG-S (RRCGYY) and CpG-I (NCCGNN and NNCGRN) deduced by published papers (Krieg et al., 1998; Lundberg et al., 2003).
e Calculated by the formula under Materials and methods. A positive value is indicative of a putatively stimulatory genome and a negative value of a putatively inhibitory genome.
f Calculated using the entire full-length or near full-length TTV sequences as found in GenBank.
g Calculated using only the segments of the GenBank sequences that could be aligned.
h Median. In parenthesis, the range of value.
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genogroup, but those in genogroup 4 were the most consistently
stimulatory (Table 3). In particular, the differences between median
CpG index of genogroup 4 and those of genogroups 3 and 5 were
statistically signiﬁcant at p=0.0099 and 0.0051, respectively. Impor-
tantly, these differences were maintained also when the CpG indexes
were calculated using only the segments of the GenBank sequences
that could be aligned, thus excluding that the fact that the near full-
length sequences lacked small parts of the genome might affect the
overall ﬁndings (p=0.038 and p=0.0036, respectively). Notably,
ViPiSAL exhibited a moderately stimulatory CpG index (4.3).Discussion
Prompted by observations that certain DNA viruses have the
potential to stimulate immune cells to produce IFNγ and other
proinﬂammatory cytokines through the unmethylated CpG motifs
present in their genomes (Lundberg et al., 2003; Malmgaard, 2004;
Basner-Tschakarjan et al., 2006; Gill et al., 2006; Guggemoos et al.,
2008), in this studywe investigatedwhether such a property is shared
by TTV. Spleen cells of BALB/c mice incubated with TTV-lipo (DNA of
ViPiSAL, a genogroup TTV isolate, complexed with lipofectin)
expressed increased levels of IFNγ, IL6, and IL10 RNAs, while the
levels of IL4 and IL12 RNAs remained unchanged. In contrast, TTV DNA
alone or lipofectin alone exerted no detectable effects. Lipofectin is
known to spontaneously incorporate DNA, protecting it against
nucleases and efﬁciently delivering it into a variety of cell types,
including spleen cells (Felgner and Ringold, 1989). It was thus
concluded that the TTV DNA used can effectively activate proin-
ﬂammatory gene transcription in immune cells, provided that it is
associated with a substance capable of protecting and delivering it
into the cells, that is of substituting for the viral capsid (Xu and Szoka,
1996). Consistent with these ﬁndings, the stimulatory effect of TTV-
lipo on spleen cells was dependent on the dose of viral DNA
incorporated in the liposomes and was reﬂected by increased
concentrations of IFNγ and IL6, but not IL4 in the supernatant of the
cultures relative to what observed with sister cultures exposed to
lipofectin alone.
We subsequently performed two inhibition experiments to assess
whether the above activity of TTV DNA was mediated by TLR9.
Chloroquine, known to inhibit TLR9 activationdue to its ability to block
endosomal acidiﬁcation, which is a prerequisite for TLR9-mediated
recognition of unmethylated DNA and signaling (Latz et al., 2004; Rutz
et al., 2004), completely blocked the activation of IFNγ, IL6, and IL10
gene expression by TTV-lipo, and the effect was conﬁrmed by
measuring the concentration of IFNγ released in the culture super-natants. Also, a mixture of TLR9-speciﬁc siRNAs inhibited TTV-lipo
induced activation of IFNγ RNA transcription by approximately 80%.
Thus, collectively theseﬁndings clearly indicated that TTVDNAactivity
is mediated mainly, if not exclusively, through TLR9. This endocytic
receptor, that is expressed in a variety of cell types and triggers signal
cascades that culminate in proinﬂammatory cytokines secretion, was
originally identiﬁed as a bacterial DNA receptor (Hemmi et al., 2000)
but was later shown to be involved in innate sensing of some complex
DNA viruses as well (Iacobelli-Martinez and Nemerow, 2007;
Sorensen et al., 2008; Rasmussen et al., 2009). Furthermore, TLR9 is
known to intervene in the induction of Th1 adaptive immune
responses and in B cell proliferation (Latz et al., 2004; Takeshita et
al., 2004; Kumagai et al., 2008a; Muller et al., 2008).
Further experiments were aimed at assessing whether TTV DNA
can modify the expression of proinﬂammatory cytokines induced by
other stimuli and made use of two well-characterized TRL9 stimu-
lants, the synthetic olideoxynucleotide ODN1826 and sheared E. coli
ssDNA. A low dose of TTV-lipo (6 μg) markedly enhanced the
expression of IFNγ, IL6, and IL10 induced in spleen cells by
ODN1826, and a similar effect, although less pronounced, was seen
with E. coli ssDNA. Interestingly, in the experiment with ODN1826
also a high dose of TTV DNA alone (24 μg) enhanced the response of
spleen cells, albeit much less than a low dose of TTV-lipo. Thus, these
ﬁndings indicated that TTV DNA has the ability to augment the
production of proinﬂammatory cytokines triggered by other TLR9
stimuli and that for this effect the requirement for lipofectin may not
be absolute. Additional investigations will be needed to establish
whether TTV maintains this ability when its DNA is combined with
increasing doses of such stimuli.
Finally, to obtain an indication of how extensively the genetic
diversity of TTV might reﬂect on the ability of its DNA to modulate
proinﬂammatory cytokine production, we made a computer analysis
and calculated the CpG index of 45 isolates belonging to all 5 TTV
genogroups, including ViPiSAL. In analogy with the great majority of
small vertebrate viruses (Karlin et al., 1994), a common feature of all
the TTVs examined was a low prevalence of CpG motifs relative to
what is expected based on a random base usage, which might suggest
a common evolutive interest at suppressing the occurrence of these
motifs (Wikstrom et al., 2007; Hoelzer et al., 2008). The CpG index
was recently introduced to predict in silico the efﬁcacy of DNAs as
lymphoid cell stimulants on the basis of the consensus CpG-S and
CpG-I motifs they contain (Lundberg et al., 2003). Although the
reliability of this index at predicting the actual stimulatory activity of
DNAs in in vivo situations has yet to be validated, there is no doubt
that it provides a reasonable comparison of their contents in CpG-S
and CpG-I motifs, consideredmajor factors, albeit not the only ones, in
determining such activity (Stacey et al., 2003). While ViPiSAL
240 J. Rocchi et al. / Virology 394 (2009) 235–242exhibited a moderately stimulatory value, the other CpG indexes
varied greatly ranging from putatively markedly stimulatory to
putatively markedly inhibitory values. CpG indexes varied widely
even among TTVs belonging to a same genogroup; however, those of
genogroup 4 were the most consistently stimulatory. Notably, similar
calculations performed on deduced ss antigenomes and double-
stranded replicative forms of the 45 isolates gave similarly varied CpG
indexes, but those of genogroup 4 were again the most stimulatory
(data not shown). Based on these ﬁndings, it would therefore appear
that different TTVs can vary widely with regard to the capacity to
activate immune cells, a circumstance that, if conﬁrmed experimen-
tally, would make it extremely difﬁcult predicting the impact the
variety of TTVs and mixtures of TTVs harbored by different people
may exert on immune cell functions. It is, however, noteworthy that
genogroup 4 TTV, which is relatively infrequent in healthy individuals,
was found at increased rates in patients with rheumatoid arthritis and
in children with particularly severe acute respiratory diseases, two
diseases in which the extent of inﬂammation contributes greatly to
clinical severity (Maggi et al., 2003, 2007).
In conclusion, these results represent the ﬁrst evidence that the
DNA of at least one TTV can activate TLR9, thereby driving immune
cells to synthesize and secrete proinﬂammatory cytokines. Since TTV
is known to extensively inﬁltrate and possibly replicate in many
tissues (Okamoto et al., 2001; Pollicino et al., 2003), continuous or
intermittent TLR9 stimulation by its DNA is likely to occur, thus
supporting the notion that TTV infection may signiﬁcantly impact on
development and severity of diseases in which inﬂammation is an
important determinant of tissue damage. A limitation of this study is
that, due to the existing difﬁculties in growing TTV in vitro, it used
viral DNA cloned in a bacterial plasmid, thus excluding the possible
intervention of the cellular methyltransferases, which extensively
methylate cytosine in vertebrate cell DNA (Hermann et al., 2004), at
attenuating the stimulatory potential of TTV DNA. The methylation
status of natural TTV DNA is unknown (Hoelzer et al., 2008), but
evidence has recently been presented that the genome of another
ssDNA virus, porcine circovirus 2, is scarcelymethylated (Wikstrom et
al., 2007). Indirect support to the idea that the immunostimulatory
activity of TTV DNA can be biologically relevant also comes from the
recent observation that the ORF2 protein of TTV inhibits cell
production of proinﬂammatory mediators in response to lipopoly-
saccharide by down-regulating nuclear factor kB, known to be
centrally involved in multiple signal transduction pathways that
activate inﬂammation, including those triggered by TLR9 (Zheng et al.,
2007). Conceivably, this ORF2 activity, as well as the generalized
suppression of CpGmotifs in TTV genomes discussed above, may have
evolved to counteract the stimulatory effect of TTV DNA on innate and
adaptive immune responses, an effect that would otherwise likely
reduce TTV ability to evade recognition and persist in infected hosts.
That different products of TTV can impact differently on the
production of soluble mediators is not surprising in view of what
observed with other viral infections (Sorensen et al., 2008; Russell,
2009) and may reﬂect the fact that they are recognized by different
receptors and/or interact with different molecular pathways. Further
studies aimed at understanding the physiopathological implications
of TTV infections are clearly warranted.
Materials and methodsTTV DNA preparation
The strategy for amplifying the complete TTV isolate (3672 nt) was
as follows: ﬁrst, a segment of 3204 nt (nt 403 to 3606) encompassing
most of the coding region and part of the UTR was ampliﬁed using an
inverse PCRwith UTR primers highly conserved among the genogroup
4 sequences in GenBank at the time of the study; subsequently, theremaining part of the viral genome (nt 3607 to 402) was ampliﬁed
with a nested PCR using primers speciﬁcally designed on ViPiSAL. The
two amplicons were then cloned into pDrive Cloning Vector (Qiagen,
Hilden, Germany) grown in TOP10 E. coli cells (Invitrogen, Carlsband,
CA), extracted with GenElute Endotoxin-free Plasmid Maxi-Prep Kit
(Sigma Aldrich, St. Louis, MO), excised by restriction enzyme
digestions, and puriﬁed by electrophoresis on 1.5% agarose gel. The
inserts were then extracted from the gels, puriﬁed, concentrated in
endotoxin-free water, and quantiﬁed spectrophotometrically. Finally,
the two inserts were mixed in equimolar proportions and stored in
aliquots at −20 °C until used. Endotoxin contamination of the
preparation was excluded by a Limulus amebocyte assay (LAL; PBI,
Milan, Italy) having a lower detection limit of 0.03 endotoxin units per
ml, while plasmid contamination was excluded by PCR ampliﬁcations
using primers speciﬁcally designed to detect selected parts of the
vector. Denaturation was carried out immediately before DNA use by
boiling for 10 min, followed by cooling on ice for 5 min. The two
amplicons were also used to obtain the complete sequence of the TTV
isolate by sequencing on the ABI 3100 Genetic Analyzer (Applied
Biosystem, Forster City, CA).
TLR9 ligands and other stimulants
The TLR9 ligands used as positive controls included the synthetic
immunostimulatory oligodeoxynucleotide ODN1826 (5'-TCCAT-
GAcgTTCCTGAcgTT-3'), which is protected against degradation by
the nuclease-resistant bases phosphorothioate and phosphodiesters
(indicated by lower and capital letters, respectively; Invivogen, San
Diego, CA), and E. coli DNA (100 μg/ml) provided as sheared ssDNA
fragments complexed with lipid-based transfection reagent (Invivo-
Gen). The ability of these reagents to activate TLR9 has been
established previously (Bauer et al., 2001). All compounds were
dissolved in ultrapure endotoxin-free water according to the manu-
facturer's recommendations and then stored in aliquots at −20 °C
until use. For cell stimulation, ODN1826 and E. coli DNA were used at
theﬁnal concentrations of 6 and 10 μg perml, respectively, throughout
the study. ConA (Sigma Aldrich) was used as TLR9-independent
stimulus at 5 μg/ml (ﬁnal concentration). Salmon sperm DNA
(InvivoGen) was dissolved 1 mg/ml in pyrogen-free water, sheared,
reduced ss before use as described above, and used as an unrelated
DNA control in TLR9 induction experiments. None of these prepara-
tions exhibited detectable endotoxin as determined by the LAL assay.
Stimulation of spleen cells ex vivo
Spleens were obtained aseptically from two 8- to 10-week-old
inbred BALB/c mice reared at our animal house. Spleen cells were put
in single-cell suspension using sterile dissection tools, washed 3 times
in abundant phosphate-buffered saline, counted, and resuspended in
RPMI 1640 medium (BioWhittaker; Cambrex Bioscience, Verviers,
Belgium) supplemented with 1% glutamine and 10% fetal calf serum
(complete medium). The stimulation tests were carried out by
exposing 3×106 cells in 1 ml of complete medium in 24-well plates
at 37°C in 5% CO2 to the indicated concentrations of TTV DNA and of
the positive and negative control stimulants. At the end of the
incubation period, cells and culture supernatants were transferred to
centrifugation tubes and separated at 500g for 10 min. The cells were
then stored as such at−80 °C, and the supernatants ﬁltered through
0.2-μm ﬁlters and stored at −20 °C until assayed for content in
cytokine RNAs and proteins, respectively. Each reagent was assayed in
triplicate wells in at least two independent experiments, and thewells
were tested individually. Based on the results of pilot experiments in
which spleen cells were stimulated using the same protocol with
ODN1826 for varying periods of time, cytokine RNAs were measured
12 h post stimulation. The cytokines released were instead measured
in supernatants collected at 8, 16, and 24 h.
241J. Rocchi et al. / Virology 394 (2009) 235–242Lipofectin
In most stimulation experiments, TTV DNA was used complexed
with the cationic liposomes lipofectin (TTV-lipo). These complexes
were generated as described earlier (Hasslung et al., 2003) before
adding to the spleen cell cultures. In brief, lipofectin (Invitrogen) was
diluted 1:4 with medium containing no serum and, after 45 min at
room temperature (r.t.), mixed with the desired amount of TTV DNA,
also diluted in serum-free medium. After additional 15 min at r.t., the
mixture was added to the wells containing the test spleen cells. Wells
containing similarly prepared lipofectin alone but no TTV DNA served
as controls.
Measurement of cytokine gene expression
Total RNA extracted from the spleen cells was reverse-transcribed
into cDNA, which was then used for quantitating cytokine and GAPDH
RNAs using real-time PCR assays. The assays were performed on ABI
PRISM 7700 (Applied Biosystem) using commercially available kits
with primers and probes speciﬁc for each murine cytokine (TaqMan
Gene Expression assays; Applied Biosystem). All samples were
ampliﬁed in triplicate, and negative PCR controls with no cDNA
template and total RNA without prior reverse transcription were
included ineach roundof tests. The relative expression ratio of cytokine
genes was calculated with the Relative Expression Software Tool
(REST; ref. Pfafﬂ et al., 2002), which allows for a relative quantiﬁcation
between groups and a normalization of the target genes with a
reference gene. This software calculates the relative expression ratio
(R) of a given cytokine gene on the basis on its real-time PCR efﬁciency
(E) and the crossing point (Cp) difference (Δ) of an unknown sample
versus a control (i.e. untreated cells). Target gene expression is
normalized against GAPDH, which in preliminary experiments with
ODN1826 and throughout the study was found not to be appreciably
modulated. The formula is: R=Etarget ΔCp target (mean control-mean sample)/
Ereference
ΔCp reference (mean control-mean sample).
Measurement of cytokine proteins
Cell-free-supernatants collected from the spleen cell cultures were
assayed for simultaneous quantiﬁcation of murine IFNγ, IL4, and IL6
by using a commercial multiplex bead-based immunoassay kit (Bio-
Plex system; BioRad). Cytokine assays were performed in duplicate as
described by the manufacturer's protocol, and each well was assayed
twice. Every experiment was repeated at least twice.
Inhibition of TLR9 activity
In some experiments, prior to use in the stimulation assays the
spleen cells were treated with chloroquine or transfected with TLR9-
speciﬁc siRNAs. The ﬁrst treatment was carried out by incubating the
cells with 10 μM chloroquine (InvivoGen) in the dark for 10 min. The
second was carried out exposing the cells to a mixture of commercial
siRNAs (MmTLR9_1HPsiRNA andMmTLR9_2HPsiRNA; Qiagen) at ﬁnal
concentration 400 nM, according to manufacturer's protocol. Brieﬂy,
the siRNAs were diluted in serum-free RPMI 1640, mixed with
HiPerfect Transfection Reagent, incubated at r.t. for 5–10 min to allow
the formation of transfection complexes, and ﬁnally added to wells
plated with 2×106 spleen cells suspended in 100 μl complete medium.
After 2 h at 37°C, 500 μl of complete mediumwere added, and, prior to
the addition of TTV DNA or control stimuli, the cultures further
incubated for 24 h to maximize TLR9 gene expression inhibition.
In silico analysis of TTV genomes for CpG index calculation
ViPiSAL and additional 44 full-length or near full-length TTV
sequences present in GenBank at the time of writing and represen-tative of the 5 TTV genogroups currently recognized were subjected
to computer-based analysis for determining the frequency of
published consensus CpG-S and CpG-I 6-mer motifs (Krieg et al.,
1998; Lundberg et al., 2003). The data thus generated were used to
calculate the CpG index of each sequence using the formula:
(ρstimolatory−ρinhibitory)×(CpG/kb)×ρCpG, where the difference be-
tween the ratio (ρ, observed frequency versus theoretical frequency)
of stimulatory and inhibitory CpG hexamer motifs was multiplied
by the total number of CpG motifs present in the TTV genome under
study (normalized to 1 kb) and the overall frequency of CpG motifs
(Lundberg et al., 2003). To exclude possible distortions deriving
from the fact that some GenBank sequences were near full-length,
CpG indexes were also calculated on the segments of the same
sequences that could be aligned (varying in length between 3.326
and 3.653 nt).
Statistical analyses
Differences between continuous variables were analyzed by the
Student's t test and Mann–Whitney test. Statistical signiﬁcance of
differences in cytokine mRNA expression was determined using REST,
which allows group-wise comparison and statistical analysis of
relative expression results in real-time PCR. A level of 0.05 was
taken to indicate statistical signiﬁcance.
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